Currently, some of the key players such as Bayer, VBL Therapeutics, Candel Therapeutics, AstraZeneca, DNAtrix, DelMar Pharmaceuticals, Oncoceutics, KaryoPharma, VBI Vaccines, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, Immunomic Therapeutics, Inovio Pharmaceuticals, MedImmune, Bristol-Myers Squibb, Laminar Pharmaceuticals, Day One Biopharmaceuticals, Servier, and others are actively working in the Glioma Market.
DelveInsight’s “Glioma Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Glioma market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Glioma market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Glioma: An Overview
A glioma is a central nervous system tumor that arises from glial stem or progenitor cells. Glial cells are a type of cell widely present in the nervous system. Gliomas mostly occur in the brain and, rarely, in the spinal cord.
Classification of gliomas is complex and based partly on the microscopic appearance of the tumor (histologic classification) and partly on the gene changes (mutations) that are implicated in tumor development. Differentiation is an important concept for the histologic classification of gliomas and refers to the “specialization” of the cell.
Gliomas can have four different grades of differentiation. Grade 1 gliomas show the highest level of differentiation and are the least malignant, while grade 4 tumors are the least differentiated and most malignant. Loss of differentiation is known as anaplasia, hence the name of several grade 3 gliomas. Grade 1 and grade 2 gliomas are often referred to as low-grade gliomas, while grades 3 and 4 are referred to as malignant gliomas. Further classification is possible depending on the genetic alterations that occurred in the affected cells.
Gliomas are caused by the accumulation of genetic mutations in glial stem or progenitor cells, leading to their uncontrolled growth. Mutated genes are typically involved in functions such as tumor suppression, DNA repair, and regulation of cell growth.
Glioma Market Key Facts
The total market size of glioma in the 7MM is around USD 1,000 million in 2022 and is projected to grow during the forecast period (2022-2032).
According to the estimates, the highest market size of glioma is from the United States in 2022.
Among the EU4 (Germany, France, Italy, Spain) and the UK, in which Germany has the maximum revenue share in 2022, while Spain has the lowest market share.
The market size of gliomas in Japan was around USD 90 million in 2022.
The total incident cases of Glioma in the 7MM comprised of around 47,000+ in 2022 and are projected to increase during the forecast period.
In the United States, Grade IV accounted for the highest number of incident cases, followed by Grade II glioma, while Grade I had the least number of cases.
Among EU4 and the UK, Germany accounted for the highest number of glioma cases, followed by France, whereas Spain had the lowest number of cases in 2022.
Japan accounted for approximately 9% of the total 7MM incident cases of glioma in 2022. These cases are expected to rise in the study period.
Glioma Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Glioma market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Glioma market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Glioma Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Glioma Epidemiology, Segmented as –
Total Incident Population of Glioma in the 7MM (2019–2032)
Grade-specific Incident Population of Glioma in the 7MM (2019–2032)
Type-specific Population of High-grade Glioma (including Diffuse Midline Glioma, Glioblastoma, and others) in the 7MM (2019–2032)
Type-specific Population of Low-grade Glioma (including Diffuse astrocytoma, Pilocytic Astrocytoma, and others) in the 7MM (2019–2032)
Glioma Cases Based on Molecular Alterations in the 7MM (2019–2032)
Age-specific Population of Glioma in the 7MM (2019–2032)
Glioma Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Glioma market or expected to be launched during the study period. The analysis covers the Glioma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Glioma pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Glioma Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/glioma-market
Glioma Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Glioma. Currently, Chimerix is leading the therapeutics market with its Glioma drug candidates in the most advanced stage of clinical development.
The Leading Players in the Glioma Therapeutics Market Include:
Aadi Bioscience, Inc., Agios Pharmaceuticals, AIVITA Biomedical, Alaunos Therapeutics, AnHeart Therapeutics Inc., Apices Soluciones S.L., AstraZeneca, Basilea Pharmaceutica, BeiGene, Beijing Pearl Biotechnology Limited Liability Company, Bexion Pharmaceuticals, Inc., BioMimetix JV, LLC, Bristol-Myers Squibb, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Chimerix, CNS Pharmaceuticals, Day One Biopharmaceuticals, Denovo Biopharma, DNAtrix, Epitopoietic Research Corporation, Erimos Pharmaceuticals, Everfront Biotech Co., Ltd., Forma Therapeutics, GlaxoSmithKline, Incyte Corporation, Istari Oncology, Istari Oncology, Inc., Kazia Therapeutics, Laminar Pharmaceuticals, Lee’s Pharmaceutical Limited, Merck & Co, Midatech Pharma US Inc., NanoPharmaceuticals LLC, NeoImmuneTech, Neonc Technologies, Inc., Nerviano Medical Sciences, Nuvation Bio Inc., Oblato, Inc., OncoSynergy, Inc., Philogen S.p.A., Plus Therapeutics, Prelude Therapeutics, PTC Therapeutics, Samus Therapeutics, Inc., Shanghai Gencells Therapeutics, SonALAsense, Inc., SpringWorks Therapeutics, Inc., Sumitomo Dainippon Pharma, Symphogen, SystImmune, TCRCure Biopharma, VBL Therapeutics, Xennials Therapeutics, and others.
Glioma Emerging and Marketed Drugs Covered in the Report Include:
AV-GBM-1: AIVITA Biomedical
DB102: Denovo Biopharma
DSP-7888: Sumitomo Dainippon Pharma
Eflornithine: Orbus Therapeutics
LAM561: Laminar Pharma
ONC 201: Chimerix
RZ 002: Rznomics
SurVaxM: MimiVax
CURB 906: Curative Biotechnology
AB-218: AnHeart Therapeutics Inc.
PVSRIPO: Istari Oncology, Inc.
YYB-103: CellabMED
OS2966: OncoSynergy
Tovorafenib: Day One Biopharmaceuticals
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Glioma Competitive Intelligence Analysis
4. Glioma Market Overview at a Glance
5. Glioma Disease Background and Overview
6. Glioma Patient Journey
7. Glioma Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Glioma Treatment Algorithm, Current Treatment, and Medical Practices
9. Glioma Unmet Needs
10. Key Endpoints of Glioma Treatment
11. Glioma Marketed Products
12. Glioma Emerging Drugs and Latest Therapeutic Advances
13. Glioma Seven Major Market Analysis
14. Attribute Analysis
15. Glioma Market Outlook (In US, EU5, and Japan)
16. Glioma Access and Reimbursement Overview
17. KOL Views on the Glioma Market
18. Glioma Market Drivers
19. Glioma Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management Solutions
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
